Physician profile
Jeffrey E Petersen
NPI 1275551707
$15,815.51
in general payments reported to CMS, 2019-2025
44 companies · $1,778 in 2025
The $1,778 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,885 · 2020: $1,883 · 2021: $2,538 · 2022: $2,212 · 2023: $2,861 · 2024: $2,657 · 2025: $1,778.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,853 · Education: $444.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,853.03 |
| Education | $443.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,538.60 | 2019-2025 | |
| Janssen Biotech, INC. | $2,036.66 | 2019-2025 | Tremfya |
| Lilly USA, LLC | $1,476.29 | 2019-2025 | Taltz, Olumiant, Ebglyss |
| Novartis Pharmaceuticals Corporation | $1,471.85 | 2019-2025 | |
| Sun Pharmaceutical Industries INC. | $1,031.48 | 2019-2024 | Ilumya, Blu-U, Odomzo |
| Ucb, INC. | $998.89 | 2019-2025 | Bimzelx, Cimzia |
| Pfizer INC. | $813.31 | 2019-2025 | |
| Amgen INC. | $671.96 | 2019-2025 | Otezla, Otezla |
| Mayne Pharma Commercial LLC | $583.86 | 2019-2025 | |
| Leo Pharma INC. | $537.89 | 2019-2024 | Adbry |
| E.R. Squibb & Sons, L.L.C. | $422.99 | 2022-2025 | Sotyktu |
| Regeneron Healthcare Solutions, INC. | $380.94 | 2021-2025 | Libtayo, Dupixent |
| Genzyme Corporation | $330.04 | 2019-2025 | |
| Incyte Corporation | $268.39 | 2021-2025 | Opzelura |
| Galderma Laboratories, L.P. | $230.39 | 2019-2024 | Oracea, Epsolay, Aklief |
Show all 44 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arcutis Biotherapeutics, INC. | $204.69 | 2023-2025 | Zoryve |
| Biofrontera INC. | $164.71 | 2022-2024 | Ameluz, Xepi, Bf-Rhodoled |
| Genentech USA, INC. | $160.68 | 2019-2024 | Actemra, Erivedge |
| Prugen, INC. Pharmaceuticals | $139.05 | 2019 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $134.95 | 2019-2025 | Cabtreo, Jublia, Siliq |
| Janssen Scientific Affairs, LLC | $125.00 | 2019 | |
| Epi Health, LLC | $112.01 | 2020-2022 | |
| Mission Pharmacal Company | $87.09 | 2019-2021 | |
| Tactile Systems Technology INC | $86.47 | 2019-2025 | Nimbl, Flexitouch Plus |
| Kerecis Limited | $79.44 | 2023-2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose, Kerecis Omega3 Graftguide |
| Strata Skin Sciences, INC. | $77.22 | 2019-2025 | Xtrac |
| Journey Medical Corporation | $77.04 | 2019-2023 | |
| Almirall LLC | $74.94 | 2020-2025 | Seysara, Klisyri |
| Celgene Corporation | $72.48 | 2019 | |
| Merz North America, INC. | $61.89 | 2019-2023 | Xeomin |
| Stimlabs LLC | $40.63 | 2025 | Allacor P |
| Dermavant Sciences, INC. | $38.32 | 2024 | Vtama |
| Vyne Pharmaceuticals INC. | $36.81 | 2020-2021 | |
| Pierre Fabre Pharmaceuticals, INC. | $31.97 | 2019 | |
| Aclaris Therapeutics, INC. | $31.92 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $31.02 | 2025 | Spevigo |
| Revance Therapeutics, INC. | $29.93 | 2025 | Daxxify |
| Dermira, INC. | $29.09 | 2020 | |
| Angiodynamics, INC. | $22.10 | 2025 | Venacure 1470 Pro |
| Boston Scientific Corporation | $21.09 | 2020 | |
| Endo Pharmaceuticals INC. | $15.21 | 2020 | |
| Sandoz INC. | $14.97 | 2020 | |
| Misonix INC | $11.94 | 2021 | |
| Cashflow Solutions, LLC | $9.31 | 2024 | Pcd-52 737a (US) White, Pcd-51 731a (US) - White, Lympha Press Optimal Plus(US) Bt |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Petersen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.